

drug encapsulated is an indolocarbazole derivative.

23. (Amended) The liposome preparation according to claim 21, wherein the drug encapsulated is an antitumor agent.

24. (Amended) The liposome preparation according to claim 21, wherein the drug encapsulated is an antibiotic.

25. (Amended) The liposome preparation according to claim 21, wherein the drug encapsulated is a pharmaceutically active substance.


REMARKS

The claims have been amended to correct their dependency and conformity with accepted U.S. practice and the specification has been changed to correct typographical errors. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lawrence S. Perry", written over a horizontal line.

Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY_MAIN 224135 v1

(National Phase of PCT Application No. PCT/JP00/04140)
 Attorney Docket No. 5.1195

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

1. (Amended) A method of [inhibiting the leakage of] preparing a drug encapsulated in liposomes [in the presence of a biological component], which comprises selecting a drug and encapsulating said drug using at least two lipid bilayers of the liposomes.

2. (Amended) A method of [inhibiting the leakage of] preparing a drug encapsulated in liposomes [in the presence of a biological component], which comprises selecting a drug and encapsulating said drug using lipid having a phase transition temperature higher than *in vivo* temperature as lipid constituting the liposomes.

3. (Amended) A method of [inhibiting the leakage of] preparing a drug encapsulated in liposomes [in the presence of a biological component], which comprises selecting a drug and encapsulating said drug satisfying at least two requirements selected from the group consisting of [the following three requirements]: using at least two lipid bilayers of the liposomes, controlling the average particle size of the liposomes to 120 nm or more, and using lipid having a phase transition temperature higher than *in vivo* temperature as lipid constituting the liposomes.

4. (Amended) The method [of inhibiting the leakage] according to claim 2 or 3, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

5. (Amended) The method [of inhibiting the leakage] according to claim 2 or 3, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

6. (Amended) [A] The method [of inhibiting the leakage of a drug encapsulated in liposomes in the presence of a biological component] according to claim 3, which comprises using at least two lipid bilayers of the liposomes, and controlling the average particle size of the liposomes to 120 nm or more.

7. (Amended) The method [of inhibiting the leakage] according to claim 3 or 6, wherein the liposomes have an average particle size of 120 to 500 nm.

8. (Amended) The method [of inhibiting the leakage] according to any one of claims 1 to [7] 3 or 6, wherein the biological component is a blood component.

9. (Amended) The method [of inhibiting the leakage] according to [any one

of] claim[s 1 to] 8, wherein the drug encapsulated is an indolocarbazole derivative.

10. (Amended) The method [of inhibiting the leakage] according to [any one of] claim[s 1 to] 8, wherein the drug encapsulated is an antitumor agent.

11. (Amended) The method [of inhibiting the leakage] according to [any one of] claim[s 1 to] 8, wherein the drug encapsulated is an antibiotic.

12. (Amended) The method [of inhibiting the leakage] according to [any one of] claim[s 1 to] 8, wherein the drug encapsulated is a pharmaceutically active substance.

13. (Amended) A liposome preparation comprising encapsulated drug, at least two [in which the number of] lipid bilayers [of the liposomes is at least two], and [the liposomes have] having an average particle size of 120 nm or more.

14. (Amended) A liposome preparation comprising encapsulated drug, at least two [in which the number of] lipid bilayers [of the liposomes is at least two, and] wherein the lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

15. (Amended) A liposome preparation [in which the] comprising an

encapsulated drug, and wherein the liposomes have an average particle size of 120 nm or more, and the lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

16. (Amended) A liposome preparation comprising an encapsulated drug, wherein said liposome [which] satisfies at least two requirements selected from the group consisting of [the following three requirements]: the number of lipid bilayers of the liposomes is at least two, the liposomes have an average particle size of 120 nm or more, and lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

19. (Amended) The liposome preparation according to any one of claims 14 to [18] 16, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

20. (Amended) The liposome preparation according to any one of claims 14 to [18] 16, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

21. (Amended) The liposome preparation according to any one of claims 13 [and], 15 [to 18] or 16, wherein the liposomes have an average particle size of 120 to 500 nm.

22. (Amended) The liposome preparation according to [any one of] claim[s]
13 to] 21, wherein the drug encapsulated is an indolocarbazole derivative.

23. (Amended) The liposome preparation according to [any one of] claim[s]
13 to] 21, wherein the drug encapsulated is an antitumor agent.

24. (Amended) The liposome preparation according to [any one of] claim[s] 13
to] 21, wherein the drug encapsulated is an antibiotic.

25. (Amended) The liposome preparation according to [any one of] claim[s]
13 to] 21, wherein the drug encapsulated is a pharmaceutically active substance.

NY_MAIN 224135v1